Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195656 | 1.00 | BACE1 (0.53) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL6821858 | 0.98 | BACE1 (0.51) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| Guanidine SCHEMBL7172098 | 0.89 | BACE1 (0.45) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL9367430 | 0.86 | AKR1C3 (0.46) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL4716666 | 0.86 | HDAC3 (0.44) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL26969012 | 0.86 | NPSR1 (0.56) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL9367435 | 0.86 | AKR1C3 (0.46) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL4716668 | 0.86 | HDAC3 (0.44) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL20475290 | 0.86 | HCAR2 (0.44) | BACE1HCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL3930273 | 0.83 | CYP1A2 (0.43) | BACE1HCAR2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | claimed |
| WO-2020252075-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-12-17 | — | — | WO | claimed |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-01-28 | — | — | US | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2017-12-21 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | CA6, CA13, EPCAM | BACE1 3605/4885HCAR2 11/4885HDAC3 2613/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | BACE1 4548/4885HCAR2 4789/4885HDAC3 3090/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | BACE1 4548/4885HCAR2 4789/4885HDAC3 3090/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | BACE1 2312/4885HCAR2 3310/4885HDAC3 1033/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | BACE1 4804/4885HCAR2 2828/4885HDAC3 849/4885 |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | CA6, CA13, EPCAM | BACE1 3605/4885HCAR2 11/4885HDAC3 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.